Recovered patient antibody treatments against COVID-19 underway
By MYBRANDBOOK
With the continuation of the COVID-19 pandemic and possible vaccines approximately one year away from launch, the race to find a treatment for the disease continues. A growing number of pharmaceutical companies have begun work on recovered patients’ antibody treatments for COVID-19. As monoclonal antibody (mAb) drugs are some of the top sellers in the market today, this approach holds potential, says GlobalData, a leading data and analytics company.
Johanna Swanson, Product Manager at GlobalData, comments: “One approach for these treatments involves identifying the most effective anti-SARS-CoV-2 antibodies from patients who have recovered from the disease. The antibodies are then mass-produced, removing the need for continued plasma from patients, and administered intravenously to current COVID-19 patients to lessen their symptoms.”
One of the companies working on this technique is GigaGen, which is looking to produce whole antibody recombinant immunoglobulin repertoires from recovered patients. The company will use its single-cell technology libraries, which can be directly translated into antibody therapies. These antibodies would be able to block the replication of the virus and be used for passive immunity after intravenous administration. The company is currently seeking recovered patients to donate plasma to begin identification and construction of the antibody libraries. The company is also working with the FDA to speed up development with a goal of reaching clinics in early 2021.
Swanson continued: “This manufacturing process has better batch consistency and lower contamination risk because it is based on a recombinant therapy and not derived from plasma. This increases the consistency as it is not dependant on batches of human plasma, which can vary, and increases its potency as it is the same specific concentrated antibodies produced in each batch.”
Another company working on this treatment is Celltrion Group. The company has completed its identification of the most promising antibody candidates from the blood of recovered patients in Korea in partnership with the Korea Centers for Disease Control and Prevention (KCDC). The company now plans to begin work on cell line development and mass production for these antibodies, with the goal of launching clinical trials in July 2020.
Swanson continues: “This novel treatment has the potential of leveraging the body’s own immune system to create a treatment. With a large number of antibodies examined, there is a high potential to find a promising candidate that has already been selected to be effective and specific. This treatment can be used to lessen the severity of the illness for patients and to provide prophylactic treatments for healthcare workers and immunocompromised individuals.”
BREAKING NEWS
TECHNO TRENDS
Nazara and ONDC set to transform in-game monetization with ‘
Nazara Technologies has teamed up with the Open Network for Digital Comme...
Jio Platforms and NICSI to offer cloud services to government
In a collaborative initiative, the National Informatics Centre Services In...
BSNL awards ₹5,000 Cr Project to RVNL-Led Consortium
A syndicate led by Rail Vikas Nigam Limited (abbreviated as RVNL), along wi...
Pinterest tracks users without consent, alleges complaint
A recent complaint alleges that Pinterest, the popular image-sharing platf...
E-Magazine
TECHNOTAINMENT
Netflix adds 'Moments' feature for saving, sharing scenes from
Netflix has introduced a new “Moments” feature on its mobile app, whic
Jacqueline Fernandez come together with YouTuber Mr. Beast for
Jacqueline Fernandez has partnered with American YouTuber Mr. Beast to b
MOVERS & SHAKERS
Visa elevates Rishi Chhabra as new Country Manager for India
Rishi holds a Master’s in Industrial Engineering from The Ohio State Univ
Genesys welcomes Albert Nel as Senior VP and Regional Sales Le
Genesys continues to deepen its investment in the APAC region. Earlier this
OPEN YOUR EYES
INTERVIEWS
AMD Pensando driving innovation in the DPU architecture space
AMD Pensando stands out in the DPU (Data Processing Unit) market with its u
Alcatel-Lucent Enterprise Carrying a 100 year legacy ahead
A good amount of R&D works and global support services are operated out of
HOT PICK
SonicWall Launches TZ80: A Powerful Solution for Remote Office
SonicWall announced today the launch of the TZ80, a groundbreaking securit
Gigabyte X3D Turbo: A Gaming Revolution
GIGABYTE X3D Turbo Mode is a cutting-edge feature that unifies cores distr
MAKE IN INDIA BRANDS
EXIDE INDUSTRIES LTD.
WIPRO LTD.
SAMRIDDHI AUTOMATIONS PVT. LTD.
DRUVA SOFTWARE PVT. LTD.
EMINENT CIO'S OF INDIA
ICONS OF INDIA
Icons Of India : NATARAJAN CHANDRASEKARAN
Natarajan Chandrasekaran (Chandra) is the Chairman of Tata Sons, the h...
ICONS OF INDIA : SANJAY GUPTA
Sanjay Gupta is the Country Head and Vice President of Google India an...
Icons Of India : Deepak Sharma
Deepak Sharma spearheads Schneider Electric India. He brings with him ...
PARTNER SPEAKERS
PSU
PFC - Power Finance Corporation Ltd
PFC is a leading financial institution in India specializing in power ...
BEL - Bharat Electronics Limited
BEL is an Indian Government-owned aerospace and defence electronics co...
GeM - Government e Marketplace
GeM is to facilitate the procurement of goods and services by various ...
VIDEOS
Top 25 Brands
Global Indian industry
Indian Tech Talent Excelling The Tech World - JAYASHREE ULLAL, President and CEO - Arista Network
Jayshree V. Ullal is a British-American billionaire businesswoman, ser...
Indian Tech Talent Excelling The Tech World - ARVIND KRISHNA, CEO – IBM
Arvind Krishna, an Indian-American business executive, serves as the C...
Indian Tech Talent Excelling The Tech World - Sanjay Mehrotra, CEO- Micron Technology
Sanjay Mehrotra, the President and CEO of Micron Technology, is at the...
STARNITE AWARDS 2024
ITFORUM 2024
CMO of the Year
WOMEN LEADERSHIP
IMAGE GALLERY
TRENDS IN TECHNOLOGY
MORE VIDEOS
ADVERTISEMENTS
TECHNOLOGY DISRUPTION
UNICORNS REVOLUTIONISING
